title: [Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC].
abstract: Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC).
  
  
  METHODS
  Modified PMC consists of medication with UFT and intraarterial infusion of 5-FU. The dose of UFT is 300 or 400 mg/day. The infusion to hepatic artery of 5-FU is performed with 500 mg/body in an outpatient clinic once a week from reservoir port for 5 hours.
  
  
  RESULTS
  The number of recurrent cases after hepatectomy was 5, and that of initial cases with unresectable HCC was 3. Three cases had tumor thrombus in the main portal branch. One patient had tumor thrombus in the inferior vena cava, which reached to the right atrium. The mean number of infusions in all cases was 21. One case showed PR, and 3 cases NC. Three of 6 mortality cases died from liver failure without tumor progression. One year survival rates of the patients with tumor thrombus in the portal trunk or IVC were 75.0%. The mean survival period of these cases was 12.5 +/- 4.2 months.
  
  
  CONCLUSIONS
  Modified PMC had no severe side effect and was effective for advanced unresectable HCC.
authors.affiliation: Hokkaido University Graduate School.
authors.forename: Toshiya
authors.initials: T
authors.lastname: Kamiyama
authors.forename: Michiaki
authors.initials: M
authors.lastname: Matsushita
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Kurauchi
authors.forename: Takahito
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Hirohumi
authors.initials: H
authors.lastname: Kamachi
authors.forename: Masao
authors.initials: M
authors.lastname: Kondo
authors.forename: Toichi
authors.initials: T
authors.lastname: Ito
authors.forename: Toshiro
authors.initials: T
authors.lastname: Ogata
authors.forename: Makoto
authors.initials: M
authors.lastname: Nishikawa
authors.forename: Satoru
authors.initials: S
authors.lastname: Todo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil